Kazia Therapeutics Executes Deal With QIMR Berghofer Medical to Obtain Intellectual Property License
Kazia Therapeutics (KZIA) said Thursday it has executed a deal with QIMR Berghofer Medical Research Institute, an Australian cancer research center, to receive a license for certain intellectual property to develop any drugs or product candidates within the PI3K inhibitor class in combination with immunotherapy or PARP inhibitors.
Financial terms weren't disclosed.
The company first partnered with the cancer research center in December 2022, Kazia added.
Shares of the company were up 3% in recent Thursday premarket activity.
Price: 0.3780, Change: +0.01, Percent Change: +3.53
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。